Clinical Trials Browser

Phase 3 × Nasopharyngeal Carcinoma × penpulimab × Clear all

NCT04974398 2025-04-13

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

296 enrolled 1 FDA

Nasopharyngeal Carcinoma